QIAGEN builds on global collaboration with Amgen for companion diagnostic development in non-small cell lung cancer
• QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA QIAGEN N.V. (NYSE: QGEN; Frankfurt Mehr